SANGAMO THERAPEUTICS, INC - Common Stock (SGMO)

Historical Holders from Q1 2014 to Q1 2025

Symbol
SGMO on Nasdaq
CUSIP
800677106
Type / Class
Equity / Common Stock
Shares outstanding
212M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
61.5M
Holdings value
$62.7M
% of all portfolios
0%
Grand Portfolio weight change
+0%
Number of holders
124
Number of buys
64
Number of sells
-44
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WASATCH ADVISORS LP 6.6% $12.9M 14M WASATCH ADVISORS LP Dec 31, 2024

Institutional Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 454K $297K +$157K $0.66 7
2024 Q4 61.5M $62.7M +$5.76M $1.02 124
2024 Q3 55.9M $48.4M -$13.2M $0.87 101
2024 Q2 86.9M $31.1M -$5.53M $0.36 126
2024 Q1 100M $67.3M +$9.87M $0.67 127
2023 Q4 86M $46.7M -$9.3M $0.54 126
2023 Q3 102M $61.2M -$4.21M $0.60 129
2023 Q2 105M $136M -$10.6M $1.30 147
2023 Q1 110M $194M +$11.8M $1.76 173
2022 Q4 103M $324M +$18.1M $3.14 174
2022 Q3 91.2M $447M +$40.1M $4.90 181
2022 Q2 88.9M $368M +$45.6M $4.14 172
2022 Q1 77.7M $452M +$17.4M $5.81 177
2021 Q4 75.5M $567M +$12.7M $7.50 175
2021 Q3 75.2M $679M -$11.4M $9.01 186
2021 Q2 76.2M $912M -$39.8M $11.97 191
2021 Q1 79.1M $991M +$8.42M $12.53 192
2020 Q4 78M $1.22B -$2.07M $15.61 211
2020 Q3 81.5M $771M +$42.8M $9.45 199
2020 Q2 77M $690M +$38.5M $8.96 193
2020 Q1 74M $471M -$44.1M $6.37 171
2019 Q4 78.4M $656M -$35.5M $8.37 183
2019 Q3 82.1M $744M +$18.2M $9.05 175
2019 Q2 79.8M $860M +$188M $10.77 174
2019 Q1 62.2M $593M +$8.48M $9.54 173
2018 Q4 63.9M $733M -$24.4M $11.48 185
2018 Q3 63.3M $1.07B +$5.36M $16.95 211
2018 Q2 64.7M $918M +$102M $14.20 204
2018 Q1 57.2M $1.09B +$32M $19.00 205
2017 Q4 55.5M $911M +$36.7M $16.40 165
2017 Q3 54.7M $820M +$37.4M $15.00 147
2017 Q2 53M $467M +$101M $8.80 143
2017 Q1 41.8M $218M +$36.4M $5.20 113
2016 Q4 41M $125M -$11.9M $3.05 119
2016 Q3 43.6M $202M -$12.3M $4.63 119
2016 Q2 46.2M $268M -$15.6M $5.79 136
2016 Q1 48.7M $292M -$3.98M $6.05 141
2015 Q4 48.8M $445M -$33.2M $9.13 137
2015 Q3 51.2M $289M -$28.4M $5.64 141
2015 Q2 49.6M $550M -$34.3M $11.09 154
2015 Q1 51M $799M +$55.4M $15.68 165
2014 Q4 46.4M $705M -$11M $15.21 157
2014 Q3 48.5M $523M +$6.23M $10.79 154
2014 Q2 46.1M $703M +$28.9M $15.27 151
2014 Q1 48.2M $871M +$75.3M $18.08 143